EARS2 — Mitochondrial Glutamyl-tRNA Synthetase

EARS2 — Mitochondrial Glutamyl-tRNA Synthetase

Introduction

EARS2 (Glutamyl-tRNA Synthetase 2, Mitochondrial) is an essential mitochondrial aminoacyl-tRNA synthetase (mtARS) that catalyzes the charging of glutamate to its cognate mitochondrial tRNA. This enzymatic function is critical for mitochondrial protein synthesis, as mtARS enzymes are required for translating the 13 proteins encoded by the mitochondrial genome. Mutations in EARS2 cause a spectrum of mitochondrial disorders, most notably Leukoencephalopathy with thalamus and Brainstem Involvement (LBSL), and have been implicated in broader neurodegenerative processes. This comprehensive analysis examines EARS2 structure, function, disease associations, and its relationship to common neurodegenerative diseases including Alzheimer's and Parkinson's.

EARS2 — Mitochondrial Glutamyl-tRNA Synthetase

Introduction

EARS2 (Glutamyl-tRNA Synthetase 2, Mitochondrial) is an essential mitochondrial aminoacyl-tRNA synthetase (mtARS) that catalyzes the charging of glutamate to its cognate mitochondrial tRNA. This enzymatic function is critical for mitochondrial protein synthesis, as mtARS enzymes are required for translating the 13 proteins encoded by the mitochondrial genome. Mutations in EARS2 cause a spectrum of mitochondrial disorders, most notably Leukoencephalopathy with thalamus and Brainstem Involvement (LBSL), and have been implicated in broader neurodegenerative processes. This comprehensive analysis examines EARS2 structure, function, disease associations, and its relationship to common neurodegenerative diseases including Alzheimer's and Parkinson's.

<div class="infobox infobox-gene">
<div class="infobox-header">EARS2 Gene Information</div>
<div class="infobox-row"><strong>Gene Symbol:</strong> EARS2</div>
<div class="infobox-row"><strong>Full Name:</strong> Glutamyl-tRNA Synthetase 2, Mitochondrial</div>
<div class="infobox-row"><strong>Chromosomal Location:</strong> 16p12.2</div>
<div class="infobox-row"><strong>NCBI Gene ID:</strong> 124454</div>
<div class="infobox-row"><strong>OMIM:</strong> 614949</div>
<div class="infobox-row"><strong>Ensembl ID:</strong> ENSG00000120784</div>
<div class="infobox-row"><strong>UniProt ID:</strong> Q5J7C6</div>
<div class="infobox-row"><strong>Gene Family:</strong> Mitochondrial aminoacyl-tRNA synthetases</div>
<div class="infobox-row"><strong>Associated Diseases:</strong> LBSL, Leigh syndrome, mitochondrial encephalopathy, Perrault syndrome</div>
</div>

Structure and Catalytic Mechanism

Protein Domain Organization

EARS2 is a Class I aminoacyl-tRNA synthetase with characteristic domain architecture:

N-terminal Domain

• Mitochondrial targeting sequence (MTS): A cleavable presequence that directs import into mitochondria
• Additional targeting elements for mitochondrial matrix localization
• Interaction domains for protein complex formation

Catalytic Domain

• Aminoacylation domain: The active site that catalyzes glutamate activation and tRNA charging
• ATP-binding pocket: Conserved KMSKS loop that binds ATP
• acceptor stem binding region: Recognizes the 3' end of tRNA

C-terminal Domain

• Helical domain: Mediates protein-protein interactions
• Dimerization interface: EARS2 functions as a dimer
• tRNA recognition elements: Additional binding surfaces for tRNA specificity

Catalytic Mechanism

EARS2 catalyzes aminoacylation through a two-step process:

This reaction requires:

• Correct amino acid recognition
• ATP binding and hydrolysis
• Specific tRNA^Glu recognition
• Proper proofreading to prevent mischarging

Structural Features

EARS2 shares structural features with other Class I synthetases:

• Rossmann fold: Central β-sheet with α-helices in catalytic domain
• HIGH motif: Sequence signature in active site
• KMSKS loop: Flexible loop that closes over ATP during catalysis
• Connective polypeptide: Links domains for conformational changes

Biological Function

Mitochondrial Translation

EARS2 is essential for mitochondrial protein synthesis:

Mitochondrial tRNA^Glu

• EARS2 specifically charges mitochondrial tRNA^Glu
• This tRNA decodes GAA/GAG codons
• Required for translation of 13 mitochondrial-encoded proteins:
• Complex I subunits: ND1, ND2, ND3, ND4, ND4L, ND5, ND6
• Complex III subunits: CYTB
• Complex IV subunits: COX1, COX2, COX3
• Complex V subunits: ATP6, ATP8

Translation Quality Control

• Accurate aminoacylation ensures proper protein synthesis
• Prevents incorporation of incorrect amino acids
• Connected to mitochondrial ribosome quality control
• Dysfunction leads to translational errors

Complex I Function

EARS2 is particularly important for Complex I (NADH:ubiquinone oxidoreductase):

• Seven Complex I subunits are encoded by mitochondrial DNA
• Requires EARS2 for translation of these subunits
• Complex I deficiency is a common finding in EARS2 mutations
• Complex I defects lead to energy deficiency

Metabolic Integration

EARS2 connects mitochondrial function to cellular metabolism:

• ATP production through oxidative phosphorylation
• Reactive oxygen species (ROS) management
• Metabolic signaling through mitochondrial function
• Integration with cellular stress responses

Expression Pattern

Tissue Distribution

EARS2 is expressed ubiquitously with highest levels in:

• Brain: Cerebral cortex, cerebellum, brainstem, thalamus
• Heart: High expression in cardiac muscle
• Skeletal muscle: Essential for muscle function
• Liver: High metabolic activity
• Kidney: Significant expression

Cellular Localization

EARS2 is localized to:

• Mitochondrial matrix: Primary location
• Mitochondrial nucleoid: Associated with mtDNA
• Ribonucleoprotein complexes: Connected to mitochondrial ribosomes

Developmental Expression

EARS2 expression varies during development:

• Embryonic: Essential for development
• Postnatal: Maintained at high levels
• Adult: Tissue-specific expression patterns
• Aging: Altered expression in some contexts

Disease Associations

Leukoencephalopathy with Thalamus and Brainstem Involvement (LBSL)

LBSL is the primary disease associated with EARS2 mutations:

Clinical Features

• Progressive leukoencephalopathy
• Predominant involvement of thalamus and brainstem
• Motor impairment (spasticity, ataxia)
• Cognitive decline
• Variable onset (infancy to adulthood)

Neuroimaging Findings

• White matter abnormalities
• Thalamic involvement
• Brainstem lesions
• Characteristic MRI patterns

Genetic Basis

• Autosomal recessive inheritance
• Biallelic EARS2 mutations
• Variable severity based on mutation type
• Founder mutations in certain populations

Leigh Syndrome

EARS2 mutations can cause Leigh syndrome:

Clinical Features

• Subacute necrotizing encephalomyelopathy
• Developmental regression
• Movement disorders
• Respiratory failure
• Usually infantile onset

Pathological Features

• Bilateral basal ganglia lesions
• Brainstem involvement
• Necrotic changes
• Energy deficiency

Combined Oxidative Phosphorylation Deficiencies

EARS2 mutations cause multiple complex deficiencies:

• Complex I deficiency most common
• Combined deficiencies in severe cases
• Variable tissue involvement
• Progressive course

Perrault Syndrome

EARS2 is associated with Perrault syndrome:

• Sensorineural hearing loss
• Ovarian dysfunction (in females)
• Variable neurological features
• Mitochondrial dysfunction

Role in Common Neurodegenerative Diseases

Alzheimer's Disease

Mitochondrial dysfunction is a hallmark of Alzheimer's disease, and EARS2 may play a role:

Mitochondrial Translation Defects

• Reduced mitochondrial translation in AD brain
• Altered expression of mtARS enzymes
• Correlation with Aβ and tau pathology
• Energy deficiency in neurons

Complex I Dysfunction

• Complex I deficiency in AD
• EARS2 contributes to Complex I subunit synthesis
• May be affected by Aβ toxicity
• Therapeutic implications

Energy Metabolism

• Glucose hypometabolism in AD brain
• Mitochondrial dysfunction contributes
• EARS2 function relates to energy production
• Connection to neuronal survival

Parkinson's Disease

EARS2 has several connections to Parkinson's disease:

Mitochondrial Dysfunction

• Primary hallmark of PD
• Complex I deficiency in substantia nigra
• EARS2 important for Complex I
• Connection to PINK1/PARKIN pathway

Alpha-Synuclein Interaction

• Mitochondrial function affects α-syn aggregation
• EARS2 may influence protein clearance
• Autophagy-lysosome pathway involvement
• Therapeutic targets

Energy Failure

• Dopaminergic neurons are energetically demanding
• Mitochondrial dysfunction leads to vulnerability
• EARS2 supports energy production
• Neuroprotection strategies

Amyotrophic Lateral Sclerosis (ALS)

EARS2 and mitochondrial translation in ALS:

• Mitochondrial dysfunction in motor neurons
• Altered mitochondrial translation
• Energy failure in disease
• Therapeutic targeting

Interaction Network

Mitochondrial Translation Machinery

EARS2 interacts with:

| Partner | Interaction Type | Function |
|---------|-----------------|----------|
| Mitochondrial Ribosome | Binding | Protein synthesis |
| tRNA^Glu | Substrate | Aminoacylation |
| Other mtARS | Complex | Translation machinery |
| Mitochondrial DNA | Proximity | Translation coupling |
| Complex I subunits | Product | Energy production |

Signaling Pathways

EARS2 connects to several pathways:

Therapeutic Implications

Gene Therapy Approaches

Targeting EARS2 for therapy:

Viral Vector Delivery

• Adeno-associated virus (AAV) vectors
• Mitochondrial targeting
• Long-term expression
• Current research stage

RNA-Based Approaches

• siRNA for mutation silencing
• mRNA delivery for protein replacement
• Antisense oligonucleotides
• Splice-modulating approaches

Small Molecule Modulators

Drug development strategies:

Mitochondrial Function Enhancers

• CoQ10 and analogs
• L-carnitine
• B-vitamins
• Metabolic modulators

Translation Modulators

• Mitochondrial protein synthesis inhibitors (caution)
• Translation enhancers
• Quality control modulators

Challenges and Opportunities

Key considerations:

• Mitochondrial gene delivery
• Tissue specificity
• Crossing the blood-brain barrier
• Combination approaches

• Disease modification potential
• Personalized medicine
• Biomarker development
• Combination therapy

Animal Models and Experimental Evidence

Knockout Studies

• EARS2 knockout is embryonic lethal
• Tissue-specific knockouts show deficiency
• Conditional models available
• Rescue experiments

Disease Models

• LBSL patient-derived cells
• Leigh syndrome models
• Transgenic approaches
• Phenotypic characterization

In Vitro Studies

• Patient fibroblasts
• Neuronal differentiation
• Mitochondrial function assays
• Translation analysis

See Also

• [Mitochondrial Translation](/mechanisms/mitochondrial-translation)
• [Complex I Deficiency](/mechanisms/complex-i-deficiency)
• [Leigh Syndrome](/diseases/leigh-syndrome)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [OXPHOS](/mechanisms/oxidative-phosphorylation)
• [Aminoacyl-tRNA Synthetases](/mechanisms/aminoacyl-trna-synthetases)

External Links

• [NCBI Gene - EARS2](https://www.ncbi.nlm.nih.gov/gene/124454)
• [Ensembl - EARS2](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000120784)
• [UniProt - EARS2](https://www.uniprot.org/uniprot/Q5J7C6)
• [OMIM - EARS2](https://www.omim.org/entry/614949)
• [Allen Brain Atlas - EARS2 Expression](https://human.brain-map.org/)

References